Benzinga | Feb 1, 2021 06:25AM EST

Dynavax Shares Up 17% Premarket; Clover and Dynavax Announced Planned Global Phase 2/3 Efficacy Trial of Adjuvanted COVID-19 Vaccine Candidate

Clover Biopharmaceuticals and Dynavax Technologies Corporation (NASDAQ:DVAX) today announced the plan to initiate a global Phase 2/3 efficacy trial with the S-Trimer COVID-19 vaccine candidate adjuvanted with CpG 1018 plus alum in the first half of 2021 with an interim analysis for vaccine efficacy potentially in the middle of 2021. The Coalition for Epidemic Preparedness Innovations (CEPI) will continue to support the development of Clover's COVID-19 vaccine candidate and will fund the development, including the Phase 2/3 trial, through licensure.